News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Active Biotech AB Interim Report Jan-Sep 2006
November 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN -- (MARKET WIRE) -- November 02, 2006 -- * Teva's Phase II study with laquinimod against MS successfully concluded
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Funding
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
November 12, 2025
·
3 min read
·
Dan Samorodnitsky
Layoffs
Metagenomi Chops 25% of Workforce, CEO To Advance Hemophilia A Program
November 12, 2025
·
2 min read
·
Tristan Manalac
Business
Phase III Fail Forces Neuphoria Into Strategic Review—With One Investor Offering a Takeover
November 12, 2025
·
1 min read
·
Tristan Manalac
Layoffs
Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset
November 10, 2025
·
2 min read
·
Dan Samorodnitsky
